share_log

Cantor Fitzgerald Reiterates Overweight on Orchard Therapeutics, Maintains $15 Price Target

Cantor Fitzgerald Reiterates Overweight on Orchard Therapeutics, Maintains $15 Price Target

坎托·菲茨杰拉德重申增持Orchard Therapeutics,维持15美元的目标股价
Benzinga ·  2023/06/27 08:18

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Orchard Therapeutics (NASDAQ:ORTX) with a Overweight and maintains $15 price target.

Cantor Fitzgerald分析师Pete Stavropoulos重申果园治疗公司(纳斯达克:ORTX)增持,并维持15美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发